A Prospective, Randomised Controlled Trial Comparing Weight-based Tinzaparin Versus Weight-based Enoxaparin for Peri-operative Thromboprophylaxis in Patients Undergoing Bariatric Surgery: Evaluation of Anti-Xa Levels and Clinical Outcomes.

Blood clots in the legs or lungs (called venous thromboembolism or VTE) are one of the most serious complications after weight loss surgery. Most blood clots occur after patients go home from hospital, within the first 30 days after surgery. To prevent blood clots, all patients having weight loss surgery receive a daily blood-thinning injection for 21 days after their operation.
Two blood-thinning injections are currently used at St Vincent's University Hospital for this purpose: enoxaparin (Clexane®) and tinzaparin (Innohep®). Both belong to a group of medicines called low molecular weight heparins (LMWHs). Patients with obesity process these medicines differently to the general population, and previous studies from our hospital have shown that fewer than 53% of patients achieve adequate blood-thinning levels with either injection when measured by a blood test called an anti-Xa level.
Patients will be randomly assigned (like a coin toss) to receive either tinzaparin or enoxaparin for 21 days after their surgery. Both injections are already in routine use at this hospital. A single extra blood sample will be taken on the second day after surgery to measure the anti-Xa level, which tells us whether the injection is providing adequate protection against blood clots. This blood sample will be taken at the same time as routine post-operative blood tests so that no additional blood draws are required.
The study will also look at rates of blood clots and bleeding events within 30 days of surgery, and will ask patients to complete a short questionnaire at their six-week follow-up appointment about their experience with the injection.

Start Date01 May 2026

Sponsor / Collaborator

University College Dublin

CTIS2024-512475-12-01

/ RecruitingPhase 4IIT

Thrombosis prophylaxis and coagulation activation during neoadjuvant treatment in pancreatic cancer - Association to prognosis and recurrence.

Start Date27 Nov 2024

Sponsor / Collaborator

University of Helsinki

NCT05735639

/ RecruitingPhase 4IIT

THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE) - a Multi-centre Assessor-blind Randomised-controlled Trial

Endovenous interventions are keyhole operations for varicose veins that are carried out from within the vein itself. Varicose veins are enlarged veins close to the surface of the skin. They are connected to the bigger deeper veins in the leg (known as deep veins). Because of this, operations to close the varicose veins can increase the chance of a blood clot forming in the deep veins. Blood clots in the deep veins happen in around 1 in 50 people after endovenous operations. A clot in the leg can cause swelling, pain, and other long-term problems. If a clot in the leg breaks off and travels to the lungs, it can cause problems with the lung' ability to move oxygen from the air into the blood and may, in rare cases, be life threatening.
Varicose vein procedures may carry a slightly higher risk of blood clot formation, and we are currently unsure if current clot reducing medicines are beneficial in preventing blood clots in people having varicose vein procedures.
This study will investigate if it is worthwhile prescribing medicines to reduce blood clots after varicose vein procedures.

Start Date22 Jan 2024

Sponsor / Collaborator

Imperial College London

100 Clinical Results associated with Tinzaparin Sodium

100 Translational Medicine associated with Tinzaparin Sodium

100 Patents (Medical) associated with Tinzaparin Sodium

509

Literatures (Medical) associated with Tinzaparin Sodium

02 Jan 2026·Cureus Journal of Medical Science

A Regional Audit on Venous Thromboembolism (VTE) Prophylaxis Compliance and Cultural Considerations in Prescribing Porcine-Derived Low-Molecular-Weight Heparins

Article

Author: Norouzi, Mohsen ; Mujahid, Isra ; Ahmed, Husain ; Ahmad, Shibbir ; Mujahid, Minahil ; Maheshwari, Geeta ; Ur-Rehman, Junaid ; Prudon, Ben

BACKGROUND:

Hospital-acquired venous thromboembolism (VTE) remains a leading cause of preventable mortality in the NHS. NICE guidelines (NG89) mandate timely risk assessment and prophylaxis, yet practice varies widely. Many low-molecular-weight heparins (LMWHs), such as tinzaparin, are porcine-derived, posing ethical challenges for patients with specific dietary or religious beliefs.

OBJECTIVE:

The objective of this study is to evaluate adherence to NICE NG89 guidelines on VTE prophylaxis across two hospitals, with a particular focus on culturally sensitive prescribing. This audit also assessed clinician awareness of LMWH origins and explored patient preferences around dietary compliance. The impact of targeted interventions was measured across two audit cycles.

METHOD:

A prospective two-cycle audit was conducted at two NHS hospitals in North East England, The James Cook University Hospital (JCUH) and University Hospital North Tees (UHNT), between March 2024 and January 2025. Patients with dietary requirements were identified via catering records and surveyed. A doctor questionnaire assessed awareness and counselling practice. Interventions included staff education, posters, prescribing alerts, and community outreach.

RESULTS:

Cycle one included 76 patients. Cycle two included 61 patients. VTE risk assessment improved by 14% at UHNT; JCUH maintained 100% compliance. However, timely prophylaxis fell in UHNT, with 80% receiving it late. Documentation and discussions regarding VTE and dietary compliance improved but remained suboptimal. Leaflet distribution rose by 10% at JCUH but was absent at UHNT. Notably, 98% (n = 137) of patients prioritised medication aligned with their beliefs, and nearly half would decline porcine-derived prophylaxis even if it prevented serious illness. Clinician questionnaire data showed 64% (n = 50) were unaware that LMWHs are animal-derived, and 94% (n = 50) did not inform patients, citing time pressures and limited knowledge.

CONCLUSION:

While guideline compliance improved following intervention, particularly for risk assessments and documentation, major gaps remain in patient communication and dietary-informed prescribing. Most patients expected transparency and alternatives to porcine-based medications. Future efforts must embed dietary screening into routine prescribing and strengthen shared decision-making through structured education and culturally competent communication strategies.

01 Jan 2026·Research and Practice in Thrombosis and Haemostasis

The Ottawa score for prediction of recurrent venous thromboembolism in cancer patients treated with tinzaparin: an individual patient data meta-analysis

Article

Author: Jara-Palomares, Luis ; Laporte, Silvy ; Mahé, Isabelle ; Poenou, Géraldine ; Girard, Philippe ; Mismetti, Patrick ; Lee, Agnès Y Y ; Sanchez, Olivier ; Meyer, Guy ; Chapelle, Céline

Background:

Risk of venous thromboembolism (VTE) recurrence remains high in patients with cancer-associated thrombosis (CAT), despite therapeutic anticoagulation. Identifying patients at risk of treatment failure is still a challenge.

Objectives:

We aimed to assess the performance of the Ottawa score in predicting VTE recurrence in a large homogeneous population of patients with CAT treated with the same anticoagulant, tinzaparin, for at least 3 months.

Methods:

Individual patient data from 3 prospective cohort studies and 1 randomized controlled trial were pooled (PROSPERO: CRD42019119907). Clinical events of interest were adjudicated by independent central adjudication committees in all 4 studies.

Results:

Among the 1413 patients included, the Ottawa score could be calculated for 1088 of whom 646 (59.4%) were classified at high risk of recurrence (Ottawa score ≥ 1). The 6-month cumulative incidence of recurrent VTE was 5.0% (95% CI, 3.2-7.8) in the Ottawa low-risk group and 8.5% (95% CI, 6.6-10.8) in the high-risk group. The area under the receiver operating characteristic curve was 0.56 (95% CI, 0.51-0.62). The sensitivity of the dichotomized Ottawa score (score ≥ 1) was 72.8% (95% CI, 62.6%-83.0%), the specificity was 41.9% (95% CI, 37.8%-45.9%), the positive predictive value was 8.6% (95% CI, 6.4%-10.8%), and the negative predictive value was 95.3% (95% CI, 93.3%-97.4%). Introducing additional predictive factors failed to significantly improve the score's performance.

Conclusions:

Despite the large number of patients and anticoagulant treatment standardization, the Ottawa score failed to accurately predict recurrent VTE in patients with CAT treated with tinzaparin.

01 Nov 2025·Research and Practice in Thrombosis and Haemostasis

Comparative safety of enoxaparin versus other low-molecular-weight heparins in cancer-associated venous thromboembolism: a real-world cohort study from RIETE

Article

Background:

Low-molecular-weight heparins (LMWHs) are widely used in the treatment of cancer-associated venous thromboembolism (VTE), yet their long-term safety profiles remain insufficiently compared in clinical practice.

Objectives:

The primary outcome was major bleeding over a 6-month follow-up. Secondary outcomes included VTE recurrence, non-major clinically relevant bleeding, and all-cause mortality.

Methods:

We analyzed 7287 patients with active cancer and acute VTE from the RIETE registry (2009-2022) who were treated with full-dose enoxaparin (n = 5628) or tinzaparin/dalteparin (n = 1659). Analyses were adjusted using multivariable Cox models, Fine-Gray competing risk models, frailty models clustered by center, and propensity score approaches.

Results:

Major bleeding occurred in 3.84% of patients receiving enoxaparin versus 2.53% in the tinzaparin/dalteparin group (adjusted hazard ratio [aHR] 1.56; 95% CI: 1.11-2.19), with consistent findings across all sensitivity analyses. Enoxaparin was also associated with higher all-cause mortality (28.3% vs 25.1%; aHR 1.22; 95% CI: 1.09-1.37). No significant differences were observed in VTE recurrence (3.59% vs 3.07%) or non-major bleeding (3.98% vs 3.25%). Importantly, during the first 10 days of therapy, major bleeding occurred in 1.2% of patients treated with enoxaparin twice-daily, compared to 0.4% with once-daily dosing and 0.1% in the tinzaparin/dalteparin group (P < .001).

Conclusion:

In this large, observational study, enoxaparin, particularly in twice-daily regimens, was associated with significantly increased risks of bleeding and mortality compared to tinzaparin/dalteparin. These findings may help refine LMWH selection and dosing strategies in patients with cancer-associated VTE and warrant further investigation in prospective studies.

News (Medical) associated with Tinzaparin Sodium

14 Apr 2026

·www.globenewswire.com

Er-Kim Signs Exclusive Distribution Agreement with LEO Pharma A/S to Commercialize LOQTORZI® (toripalimab) for Nasopharyngeal and Oesophageal Cancers

Er-Kim announces exclusive partnership with LEO Pharma A/S to launch LOQTORZI® across Central and Eastern Europe, expanding access to innovative cancer treatment for Nasopharyngeal and Oesophageal CancersISTANBUL and BALLERUP, Denmark, April 14, 2026 (GLOBE NEWSWIRE) -- Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies in the EMEA region, today announced that it has signed an exclusive agreement with LEO Pharma A/S to commercialize LOQTORZI® (toripalimab) in select regions in Central and Eastern Europe (CEE). Under the terms of the agreement, Er-Kim will serve as the exclusive commercial partner for LOQTORZI® in the following markets: Bulgaria, Croatia, Czechia, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia, and Slovenia. This PD-1 inhibitor is an intravenous immunotherapy that harnesses the body’s immune system to identify and attack cancer cells. In the European Union, the treatment is indicated for two distinct, hard-to-treat malignancies: Nasopharyngeal Carcinoma (NPC): A rare and aggressive cancer of the head and neck. The therapy is used in combination with cisplatin and gemcitabine for adults with recurrent (non-resectable) or metastatic NPC as a first-line option, or as a monotherapy for those who have previously undergone chemotherapy.Oesophageal Squamous Cell Carcinoma (OSCC): For patients with advanced, recurrent, or metastatic OSCC that cannot be removed by surgery. In these cases, it is used in combination with cisplatin and paclitaxel. Cem Zorlular, Chief Executive Officer of Er-Kim, said, “Advancements in immunotherapy are fundamentally changing the outlook for patients with nasopharyngeal carcinoma and oesophageal squamous cell carcinoma, but innovation only matters when it reaches the people who need it. By leveraging our deep infrastructure and relationships in Central and Eastern Europe, we are pleased to partner with LEO Pharma to bridge this access gap and bring LOQTORZI® to oncology patients throughout the CEE region.” “We are committed to advancing cancer care by making innovative treatments available to this vulnerable group of patients who face limited options. Er‑Kim’s regional knowledge makes them a strong partner to bring LOQTORZI® to new markets in Central and Eastern Europe,” said Jean Monin, Executive Vice President of the Critical Care Business Unit at LEO Pharma A/S. “Together, we can make a difference for the patients and healthcare professionals we serve.” In 2025, LEO Pharma A/S was granted exclusive distribution and sales rights for LOQTORZI® in the European Union (EU), the European Economic Area (EEA), as well as Switzerland and the United Kingdom, while TopAlliance Biosciences remains the Marketing Authorisation Holder (MAH). About Er-Kim Established in 1981, Er-Kim stands at the forefront of biopharmaceutical innovation, setting new commercialization and patient access standards. Through strategic partnerships with over 40 global leaders, Er-Kim distributes more than 68 products to 50+ countries, revolutionizing patient care in international markets by solving complex distribution challenges. Er-Kim has a dedicated team of over 400 professionals worldwide and revenues exceeding EUR 390M. For more information, please visit www.er-kim.com. About LEO Pharma's Critical Care business unitWith over 80 years of expertise in heparin production, LEO Pharma’s Critical Care unit is a global player in thrombosis. Anchored by innohep® and other established products, we leverage a specialty hospital commercial platform to drive growth through expansion into cancer-associated thrombosis and broader critical care. In 2024, the Critical Care business unit contributed 18% of total revenue of LEO Pharma. About LEO Pharma LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people’s lives, and our broad portfolio of treatments serves close to 100 million patients in over 70 countries annually. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. Headquartered in Denmark, LEO Pharma has a team of 4,000 people worldwide. Together, we reach far beyond the skin. For more information, visit www.leo-pharma.com. Media contact: Rosalia ScampoliMarketcom PRTel: (914) 815-1465rscampoli@marketcompr.com

17 Jul 2025

·www.fiercepharma.com

Leo Pharma's slow response to app lapse scolded by UK marketing watchdog

Leo Pharma accepted that “appropriate actions were not taken to rectify the issue immediately” with its Innohep app. Leo Pharma’s inaccurate Innohep app has prompted a slap-down from the PMCPA. The U.K. marketing watchdog ruled Leo brought discredit on the pharma industry by leaving the app live for three months after the errors were discovered. Two healthcare professionals complained to the PMCPA about an app for patients prescribed Innohep, Leo’s tinzaparin sodium product. The app presented information from the patient information leaflet, and users were prompted to select their prescribed dosage and shown information on injection technique.Both complainants flagged inaccuracies in the dosing information presented in the app. A Leo employee identified the errors in August 2024, and Leo’s medical affairs team learned of the inaccuracies the next day, according to the PMCPA report, yet the app was still available when the PMCPA contacted Leo in November. Leo deactivated the app and made an updated version available within two weeks of being contacted by the PMCPA.Responding to the marketing authority, Leo said two senior medical affairs employees concluded that the full volume of the syringe would always be administered, despite any conflicting information in the app, and, as such, the inaccuracies didn’t affect patient safety. The PMCPA panel took a dim view of Leo’s conclusion, stating that inaccurate dosing information is a serious matter regardless of the likelihood of a safety issue. The panel said it “was extremely concerned about Leo Pharma’s lack of urgency” and the company’s “conscious decision to keep the app live with the inaccuracies for approximately three months.” The dosage volume inaccuracies and failure to withdraw the app immediately could “reduce confidence in the industry being able to produce patient material to the required quality standards,” the panel said.Leo accepted that “appropriate actions were not taken to rectify the issue immediately.” The company listed mitigating factors that may have played a role in the failings, including a disruption that affected the company from July, when the app was certified, to October, when Leo was still working through its response to the inaccuracies. “At the time of this issue occurring there was a reorganization of the thrombosis business impacting resource and headcount; many colleagues’ roles were placed at risk of redundancy. There was no dedicated medical support for the U.K. thrombosis business at this time,” Leo said. “Whilst this does not negate the seriousness of the issue and decisions made, we believe this to be a contributing factor.”The PMCPA appeal board opted against imposing additional sanctions on Leo. The board reached the decision after assessing Leo’s work to enhance its governance, train staff and update its processes to add checks and scrutiny. Leo said “it was not experienced with creating and managing apps and had relied on external expertise,” according to the PMCPA, and would act differently if in the same situation today.

Patent Infringement

06 Nov 2023

·www.prnewswire.com

Global Antithrombotic/Anticoagulant Drugs Market Set to Reach $46.2 Billion by 2028 with a 7.9% CAGR

DUBLIN, Nov. 6, 2023 /PRNewswire/ -- The "Antithrombotic/Anticoagulant Drugs: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering. The global antithrombotic/anticoagulant drugs market is expected to reach $46.2 billion in 2028 from $31.6 billion in 2023 at a CAGR of 7.9%. This report discusses the implications of the trends mentioned above in the context of the current size and growth of the antithrombotic/anticoagulant drugs market, in global terms and by the most important national markets. Companies in the relevant pharmaceutical and medical industries are discussed, with profiles of the leaders and an update on M&A activity. Five-year global sales forecasts are provided for the leading drug categories and the country offers breakdowns of the antithrombotic/anticoagulant drugs market. Major players, competitive intelligence, innovative technologies, market dynamics and regional opportunities are discussed in detail. The report examines recent developments and product portfolios of major players. The patent analysis focuses on technological trends in recent years in regions such as the U.S., Europe, and Japan. The report presents a market analysis and estimates the compound annual growth rate (CAGR) for the antithrombotic/anticoagulant drugs market. This report segments the global market by these geographic regions: North America, Europe, Asia-Pacific, and the Rest of the World. For market estimates, data are provided for 2022 as the base year, forecasted through 2023-2028. Companies Mentioned Bayer AG Boehringer Ingelheim International GmbH Bristol Myers Squibb Daiichi Sankyo Co. Ltd. F. Hoffmann-La Roche Ltd. Johnson & Johnson Services Inc. Merck & Co. Inc. Pfizer Inc. Sanofi Report Includes 59 data tables and 35 additional tables Overview and an up-to-date analysis of the global markets for antithrombotic/anticoagulant drugs for the treatments of thrombotic (cardiovascular) disease Analyses of the global market trends, with historical market revenue data (sales figures) from 2020 to 2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028 Examination of the market potential for antithrombotic/anticoagulant drugs, and quantification of the global market for these drugs and its market segments and sub-segments over the next five years Estimate of the actual market size and revenue forecast for the market, and corresponding market share analysis based on product type, application and region In-depth information (facts and figures) pertaining to the market drivers, challenges, opportunities and prospects, as well as the technologies, regulatory scenarios and impact of COVID-19 A look at the major vendors in the global market for antithrombotic/anticoagulant drugs, and analysis of the healthcare industry structure, including market shares and recent mergers and acquisitions (M&A) activity Review of key patent grants and a look at breakthrough innovations, novel products, upcoming trends and technologies, and emerging applications for cardiovascular treatments Insight into the importance of ESG in the worldwide market, with a look at consumer attitudes, risks and opportunities assessment, and ESG practices followed by manufacturers and service providers Identification of the major stakeholders, and analysis of the competitive landscape based on recent developments, key financials and segmental revenues, and operational integration Profiles of the leading market players The following are the main conclusions reached in this report regarding antithrombotic and anticoagulant drugs: Recent innovations and the emergence of novel thrombin inhibitors have led to the decrease in revenue of traditional anticoagulants such as heparin and Vitamin K antagonists. Low molecular weight heparins, such as Fragmin (-11.8%) and Innohep (-14.1%), have seen a significant decrease in the market. The anticoagulant drug market will continue to grow at a slow rate compared to antiplatelet and thrombin inhibitors segment due to the lack of new drug launches since the expiration of the patent on Plavix. The anticoagulant segment is expected to decline soon as prices fall and the market for novel thrombin inhibitors grows. The market for thrombin inhibitors is expected to grow at the highest CAGR of 8.1% over the forecast period of 2023 to 2028. Xarelto (rivaroxaban), Eliquis (apixaban), TNKase (tenecteplase) and Savaysa (edoxaban) are the major contributors to the high growth rate of thrombin inhibitors. An aging population and the increased prevalence of cardiovascular disease worldwide fueled by a Westernized diet and lifestyle have created new opportunities for antithrombotic/ anticoagulant drug products. Key Topics Covered: Chapter 1 Introduction Chapter 2 Summary and Highlights Market Outlook Market Summary Chapter 3 Market Overview Overview of Cardiovascular Disease Coronary Artery Disease Atherosclerosis Angina (Angina Pectoris) Acute Myocardial Infarction Medical Management Lifestyle Changes Diet Modification Smoking Cessation Pharmaceuticals Anticoagulants and Antiplatelet Drugs Major Drivers Coagulation Factors Targeted to Reduce Cvd The Global Burden of Cardiovascular Disease 2030 Global Burden of Cardiovascular Disease The Global Economic Burden of Cardiovascular Disease Sales Performance of Major Drugs in 2022 Chapter 4 Global Market for Anticoagulant Drugs Overview Products Low Molecular Weight Heparin Oral Anticoagulants (Vitamin K Antagonists) Global Anticoagulant Drugs Market Forecast Chapter 5 Global Market for Antiplatelet Drugs Overview Products Oral Antiplatelets Global Antiplatelet Drugs Market Forecast Chapter 6 Global Market for Thrombin Inhibitors Overview Products Direct Thrombin Inhibitors Thrombolytic Agents Direct Factor Xa Inhibitors Global Thrombin Inhibitors Market Forecast Chapter 7 Global Market for Antithrombotic/Anticoagulant Drugs by Region Overview North America Europe Asia-Pacific Rest of the World Chapter 8 Sustainability in the Market for Antithrombotic/Anticoagulant Drugs: An ESG Perspective Introduction to ESG Sustainability in Market for Antithrombotic/Anticoagulant Drugs: An ESG Perspective Key ESG Issues Consumer Attitudes Towards ESG Industry ESG Performance Analysis Case Study Concluding Remarks Chapter 9 Clinical Trials and Patent Landscape Clinical Trials Analysis Patent Analysis Patent by Assignee Chapter 10 M&A and Venture Funding Outlook Chapter 11 Competitive Landscape Chapter 12 Company Profiles Chapter 13 Appendix For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

100 Deals associated with Tinzaparin Sodium

External Link

KEGG	Wiki	ATC	Drug Bank
D06398	Tinzaparin Sodium	B01AB10	DB06822

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pulmonary Embolism	United States	LEO Pharma A/S	14 Jul 2000
Venous Thrombosis	United States	LEO Pharma A/S	14 Jul 2000
Thrombosis	Canada	Novo Nordisk Canada, Inc.	31 Dec 1994

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Venous Thromboembolism	Phase 3	Greece	LEO Pharma A/S	30 Jan 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05625932 (PROTINCOL, Pubmed \| BMC Cancer)	Phase 3	Metastatic Colorectal Carcinoma First line	526	Tinzaparin	svyskpuhqb(zxhltggzau) = lrhbokkozx uyyajkusnh (sslhnqqacx ) View more	Positive	17 Nov 2025
ERS2024	Not Applicable	Thrombosis	511	Tinzaparin	vxipuzuzam(gojzpakzda) = muscwtzteg qpfubkezam (xmsrqlnasj )	Positive	07 Sep 2024
ISTH2022	Not Applicable	Superficial Thrombophlebitis	147	tinzaparin	zsmiprftmf(igplcskufp) = fuzimjozst dddjxljles (otuapvkutg )	-	09 Jul 2022
Onco-CAST (ASCO2022)	Phase 4	Colorectal Cancer	175	Tinzaparin 8.000 Anti-Xa IU	lruzkrytfh(vuseddinrx) = petbxhmupp fzwqewfsqp (vybteahuwt, 2.3 - 8.8) View more	-	02 Jun 2022
NCT01455831 (Periop-01, ASCO_GI2022) Manual	Phase 3	Colorectal Cancer	602	Tinzaparin Sodium (Extended peri-operative thromboprophylaxis)	ssroiwrhfk(zileozpviw) = cryhmiwhda fvhtofsemv (jyosaehnwc ) View more	Non-superior	19 Jan 2022
NCT01455831 (Periop-01, ASCO_GI2022) Manual	Phase 3	Colorectal Cancer	602	Tinzaparin Sodium (Standard thromboprophylaxis)	ssroiwrhfk(zileozpviw) = cecnfoliqc fvhtofsemv (jyosaehnwc ) View more	Non-superior	19 Jan 2022
iCaLT study (ERS2021)	Not Applicable	Lung Cancer	60	Tinzaparin 0.5 ml, 10.000 Anti-Xa IU	sexyxusjgf(ysmnosxvem) = Low in patients with bleeding compared to others mxxjiaduns (myatxztceb )	Positive	05 Sep 2021
TROPIQUE (ISTH2020)	Not Applicable	Thrombosis	-	Long-term tinzaparin treatment	hogsxurvxg(qdsnwaumrg) = quvhzyftqc afxenrzgsy (wioekkscrs ) View more	Positive	12 Jul 2020
ISTH2020	Not Applicable	Venous Thromboembolism	287	Weight-adjusted Tinzaparin	ezhjeqremi(trsbotcuoa) = nmnoqbgbdt fjcvulqsbq (vzamapxtls )	-	12 Jul 2020
ISTH2020	Not Applicable	Venous Thromboembolism	287	No prophylaxis or subcutaneous UFH	ezhjeqremi(trsbotcuoa) = ahwrajkovz fjcvulqsbq (vzamapxtls )	-	12 Jul 2020
PROSPERO CRD42020139413 (ISTH2020)	Not Applicable	Chronic Kidney Diseases	1,831	Tinzaparin	uzljfpllif(dcaemdndpk) = xtuhxzvxpr mngocbfsae (fwzhbwyoja, (0.85 - 3.61)) View more	-	12 Jul 2020
NCT01130025 (CATCH Study \| IN 0901 INT, Pubmed \| Thromb Haemost)	Phase 3	Hemorrhage \| Neoplasms \| Renal Insufficiency ... View more	864	tinzaparin	yixyvnldjx(dgkzuubjul) = xiesnmxitv vfbrafwoqw (zicblinzex ) View more	-	01 May 2018
	Phase 3	Hemorrhage \| Neoplasms \| Renal Insufficiency ... View more	864	warfarin	yixyvnldjx(dgkzuubjul) = khggwtxbtw vfbrafwoqw (zicblinzex ) View more	-	01 May 2018

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Tinzaparin Sodium

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation